C
Charles Y. Lin
Researcher at Baylor College of Medicine
Publications - 128
Citations - 19573
Charles Y. Lin is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Transcription factor & Enhancer. The author has an hindex of 42, co-authored 116 publications receiving 15889 citations. Previous affiliations of Charles Y. Lin include Harvard University & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Taming of the beast: shaping Myc-dependent amplification.
TL;DR: A synthesis of recent experimental observations offers a consensus on the direct transcriptional function of Myc: when overexpressed, Myc broadly engages the established euchromatic cis-regulatory landscape of the cell, where the factor generally amplifies transcription.
Journal ArticleDOI
Transcriptional landscape of the human cell cycle
Yin Liu,Yin Liu,Sujun Chen,Sujun Chen,Sujun Chen,Su Wang,Su Wang,Fraser Soares,Martin Fischer,Fei-Long Meng,Zhou Du,Zhou Du,Zhou Du,Charles Y. Lin,Clifford A. Meyer,James A. DeCaprio,Myles Brown,X. Shirley Liu,Housheng Hansen He,Housheng Hansen He +19 more
TL;DR: This study provided a comprehensive view of the transcriptional landscape across the cell cycle and revealed lag between transcription and steady-state RNA expression at the cell-cycle level and characterized a large amount of active transcription during early mitosis.
Journal ArticleDOI
Small-molecule targeting of brachyury transcription factor addiction in chordoma.
Tanaz Sharifnia,Mathias Wawer,Ting Chen,Qingyuan Huang,Qingyuan Huang,Barbara A. Weir,Barbara A. Weir,Ann E. Sizemore,Ann E. Sizemore,Matthew A. Lawlor,Amy Goodale,Glenn S. Cowley,Glenn S. Cowley,Francisca Vazquez,Christopher J. Ott,Joshua M. Francis,Slim Sassi,Patricia Cogswell,Hadley E. Sheppard,Tinghu Zhang,Nathanael S. Gray,Paul A. Clarke,Julian Blagg,Paul Workman,Josh Sommer,Francis J. Hornicek,Francis J. Hornicek,David E. Root,William C. Hahn,William C. Hahn,James E. Bradner,James E. Bradner,Kwok K. Wong,Paul A. Clemons,Charles Y. Lin,Joanne Kotz,Stuart L. Schreiber,Stuart L. Schreiber,Stuart L. Schreiber +38 more
TL;DR: Together, these data demonstrate small-molecule targeting of brachyury transcription factor addiction in chordoma, identify a mechanism of T gene regulation that underlies this therapeutic strategy, and provide a blueprint for applying systematic genetic and chemical screening approaches to discover vulnerabilities in genomically quiet cancers.
Journal ArticleDOI
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Mei Zeng,Nicholas Kwiatkowski,Tinghu Zhang,Behnam Nabet,Mousheng Xu,Yanke Liang,Chunshan Quan,Jinhua Wang,Mingfeng Hao,Sangeetha Palakurthi,Shan Zhou,Qing Zeng,Paul Kirschmeier,Khyati Meghani,Alan L. Leggett,Jun Qi,Geoffrey I. Shapiro,Joyce F. Liu,Ursula A. Matulonis,Charles Y. Lin,Panagiotis A. Konstantinopoulos,Nathanael S. Gray +21 more
TL;DR: This study indicates that targeting these transcriptional CDKs with agents such as THZ1 may be an effective approach for MYC-dependent ovarian malignancies.
Journal ArticleDOI
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
Haikuo Zhang,Jun Qi,Jaime M. Reyes,Lewyn Li,Prakash Rao,Fugen Li,Charles Y. Lin,Jennifer A. Perry,Matthew A. Lawlor,Alexander J. Federation,Thomas De Raedt,Yvonne Y. Li,Yan Liu,Melissa Duarte,Yanxi Zhang,Grit S. Herter-Sprie,Eiki Kikuchi,Julian Carretero,Charles M. Perou,Jacob B. Reibel,Joshiawa Paulk,Roderick T. Bronson,Hideo Watanabe,Christine Fillmore Brainson,Carla F. Kim,Peter S. Hammerman,Myles Brown,Karen Cichowski,Henry W. Long,James E. Bradner,Kwok-Kin Wong +30 more
TL;DR: The causal role of EZH2 overexpression in NSCLC is demonstrated with new genetically engineered mouse models of lung adenocarcinoma, and a potent open-source EZh2 inhibitor, JQEZ5, is developed that promotes regression of EzH2-driven tumors in vivo, revealing a potential role for anti-EZH1 therapy in lung cancer and providing the rationale for epigenetic therapy in a subset of lung cancer.